These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27307405)

  • 1. Comparative in vitro killing of canine strains of Staphylococcus pseudintermedius and Escherichia coli by cefovecin, cefazolin, doxycycline and pradofloxacin.
    Blondeau JM; Shebelski SD
    Vet Dermatol; 2016 Aug; 27(4):267-e63. PubMed ID: 27307405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro killing of canine strains of Staphylococcus pseudintermedius and Escherichia coli by cefazolin, cefovecin, doxycycline and pradofloxacin over a range of bacterial densities.
    Blondeau JM; Fitch SD
    Vet Dermatol; 2020 Jun; 31(3):187-e39. PubMed ID: 31825131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine.
    Bennie CJ; To JL; Martin PA; Govendir M
    Aust Vet J; 2015; 93(1-2):40-5. PubMed ID: 25622709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study on the comparative minimum inhibitory and mutant prevention concentration values for moxifloxacin and pradofloxacin against canine and human isolates of Staphylococcus pseudintermedius and S. schleiferi.
    Plowgian C; Blondeau JM; Levinson M; Rosenkrantz W
    Vet Dermatol; 2019 Dec; 30(6):481-e142. PubMed ID: 31486554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of cefovecin disk-diffusion test for predicting mecA gene-containing strains of Staphylococcus pseudintermedius and clinical efficacy of cefovecin in dogs with superficial pyoderma.
    Iyori K; Toyoda Y; Ide K; Iwasaki T; Nishifuji K
    Vet Dermatol; 2013 Feb; 24(1):162-7.e35-6. PubMed ID: 23331693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro comparison of Staphylococcus pseudintermedius susceptibility to common cephalosporins used in dogs.
    Westermeyer RR; Roy AF; Mitchell MS; Merchant SR
    Vet Ther; 2010; 11(3):E1-9. PubMed ID: 20960413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of canine and feline bacterial pathogens to pradofloxacin and comparison with other fluoroquinolones approved for companion animals.
    Schink AK; Kadlec K; Hauschild T; Brenner Michael G; Dörner JC; Ludwig C; Werckenthin C; Hehnen HR; Stephan B; Schwarz S
    Vet Microbiol; 2013 Feb; 162(1):119-26. PubMed ID: 22939523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal properties of pradofloxacin against veterinary pathogens.
    Silley P; Stephan B; Greife HA; Pridmore A
    Vet Microbiol; 2012 May; 157(1-2):106-11. PubMed ID: 22209121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Killing of Canine Urinary Tract Infection Pathogens by Ampicillin, Cephalexin, Marbofloxacin, Pradofloxacin, and Trimethoprim/Sulfamethoxazole.
    Blondeau JM; Fitch SD
    Microorganisms; 2021 Nov; 9(11):. PubMed ID: 34835405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activity of pradofloxacin and marbofloxacin against coagulase-positive staphylococci in a pharmacokinetic-pharmacodynamic model based on canine pharmacokinetics.
    Körber-Irrgang B; Wetzstein HG; Bagel-Trah S; Hafner D; Kresken M
    J Vet Pharmacol Ther; 2012 Dec; 35(6):571-9. PubMed ID: 22276681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat.
    Blondeau JM; Borsos S; Blondeau LD; Blondeau BJ
    Vet Microbiol; 2012 Mar; 155(2-4):284-90. PubMed ID: 21925810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antimicrobial activity of nitrofurantoin against Escherichia coli and Staphylococcus pseudintermedius isolated from dogs and cats.
    Maaland M; Guardabassi L
    Vet Microbiol; 2011 Aug; 151(3-4):396-9. PubMed ID: 21482044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of oral pradofloxacin administration in dogs.
    Boothe DM; Bush KM; Boothe HW; Davis HA
    Am J Vet Res; 2018 Dec; 79(12):1268-1276. PubMed ID: 30457901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of cefovecin in dogs.
    Stegemann MR; Sherington J; Blanchflower S
    J Vet Pharmacol Ther; 2006 Dec; 29(6):501-11. PubMed ID: 17083454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections.
    Jain JG; Housman ST; Nicolau DP
    J Antimicrob Chemother; 2014 Sep; 69(9):2443-7. PubMed ID: 24827890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cefovecin on the fecal flora of healthy dogs.
    Lawrence M; Kukanich K; Kukanich B; Heinrich E; Coetzee JF; Grauer G; Narayanan S
    Vet J; 2013 Oct; 198(1):259-66. PubMed ID: 23702279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity and spectrum of cefovecin, a new extended- spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America.
    Stegemann MR; Passmore CA; Sherington J; Lindeman CJ; Papp G; Weigel DJ; Skogerboe TL
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2286-92. PubMed ID: 16801403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones.
    Gottlieb S; Wigney DI; Martin PA; Norris JM; Malik R; Govendir M
    Aust Vet J; 2008 Apr; 86(4):147-52. PubMed ID: 18363989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius.
    Awji EG; Tassew DD; Lee JS; Lee SJ; Choi MJ; Reza MA; Rhee MH; Kim TH; Park SC
    Vet Dermatol; 2012 Aug; 23(4):376-80, e68-9. PubMed ID: 22409306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial activity of chemotherapeutic drugs against Escherichia coli and Staphylococcus pseudintermedius.
    Campbell O; Gagnon J; Rubin JE
    Lett Appl Microbiol; 2019 Nov; 69(5):353-357. PubMed ID: 31508840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.